This page shows the latest tramiprosate news and features for those working in and with pharma, biotech and healthcare.
Earlier this week another drug in that category, Alzheon’s tramiprosate, also reported some encouraging data in a mid-stage trial, although that involved a subgroup of patients with a genetic
The cognitive effect increased significantly with time, suggesting a potential disease-modifying effect of tramiprosate," they conclude. ... Tramiprosate is thought to work by inhibiting the aggregation of beta amyloid monomers into toxic oligomers.
Another once-promising anti-amyloid drug, tramiprosate, was also abandoned by Bellus Health due to inconclusive phase III study findings.
Tramiprosate is a B-amyloid inhibitor that is currently in phase III development with Neurochem. ... Data presented at ICAD 2006 showed tramiprosate halts B-amyloid-induced neuronal cell death in rats.
A promising late-stage candidate is Neurochem's Alzhemed (tramiprosate). This drug works by mimicking and binding to glycosaminoglycan (GAG), which promotes the formation of the amyloid-beta plaques.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....